Replies to post #134528 on Biotech Values

[ghmm]

I found this quote interesting

"I don't really have concern about the level of safety (of biosimilars)," he said. "What is a question-mark is efficacy, since many biotechnology products are now being improved."

Isn't a concern of the FDA added risk of immunogenicity?